Regulatory PathRegulatory requirements compared

Active substance

Onabotulinumtoxina

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
BOTOX50 UNITS/VIAL; 100 UNITS/VIAL; 200 UNITS/VIALvial · single-useALLERGANPrescription9 Dec 1991
BOTOX COSMETIC50 UNITS/VIAL; 100 UNITS/VIALvial · single-useALLERGANPrescription9 Dec 1991

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
BOTOX01981501100 UNIT / VIALPOWDER FOR SOLUTION · INTRADERMAL; INTRADETRUSORIAL; INTRAMUSCULARABBVIE CORPORATION
BOTOX0253157750 UNIT / VIALPOWDER FOR SOLUTION · INTRAMUSCULAR; INTRADERMAL; INTRADETRUSORIALABBVIE CORPORATION
BOTOX02531585200 UNIT / VIALPOWDER FOR SOLUTION · INTRAMUSCULAR; INTRADETRUSORIAL; INTRADERMALABBVIE CORPORATION
BOTOX COSMETIC02243721100 UNIT / VIALPOWDER FOR SOLUTION · INTRAMUSCULARABBVIE CORPORATION

Safety signals and safety-related labeling changes

  • US FDA 18 Oct 2024 BOTOX — safety-related labeling change
    Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for onabotulinumtoxina →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.